Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Medical University of Vienna |
---|---|
Information provided by: | Medical University of Vienna |
ClinicalTrials.gov Identifier: | NCT00280514 |
Penetration of cefpirome and moxifloaxacin into abscess fluid of humans will be tested. Patients with an abscess scheduled for drainage will receive study drugs (single or multiple dose), pus samples and plasma samples will be collected and analyzed by HPLC. Pharmacokinectics of the study drugs in pus and plasma will be determined using a pharmacokinetic model.
Condition | Intervention | Phase |
---|---|---|
Abscess or Abdominal Cyst |
Drug: cefpirome and moxifloxacin administration |
Phase IV |
Study Type: | Interventional |
Study Design: | Non-Randomized, Uncontrolled, Pharmacokinetics Study |
Official Title: | Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration |
Estimated Enrollment: | 20 |
Study Start Date: | January 2006 |
Ages Eligible for Study: | 18 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Christian Joukhadar, MD | 00431404002981 | christian.joukhadar@meduniwien.ac.at |
Contact: Robert Sauermann, MD | 00431404002981 | robert.sauermann@meduniwien.ac.at |
Austria | |
Medical University Vienna | Recruiting |
Vienna, Austria, 1090 |
Principal Investigator: | Christian Joukhadar, MD | Medical University of Vienna, Dep. of Clinical Pharmacology |
Study ID Numbers: | abscess-cef-moxi, EUdraCT no. 2005-004455-35 |
Study First Received: | January 20, 2006 |
Last Updated: | January 20, 2006 |
ClinicalTrials.gov Identifier: | NCT00280514 |
Health Authority: | Austria: "Bundesministerium für Gesundheit und Frauen" |
abscesss penetration antibiotics cefpirome moxifloxacin |
Cefpirome Moxifloxacin Abscess |
Suppuration Cysts Inflammation |
Anti-Infective Agents Anti-Bacterial Agents Pathologic Processes |
Therapeutic Uses Infection Pharmacologic Actions |